Clinical trial
Treatment of Adult Ph+ LAL With BMS-354825
NCT00391989 · Gruppo Italiano Malattie EMatologiche dell'Adulto, Other · Completed
Key facts
| NCT number | NCT00391989 |
|---|---|
| Title | Treatment of Adult Ph+ LAL With BMS-354825 |
| Official title | A Phase II Multicenter Study on the Treatment of Adult de Novo Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) With the Protein Tyrosine Kinase Inhibitor BMS-354825. EudraCT Number 2005-005107-42. |
| Lead sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoblastic Leukemia, Acute |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Enrollment | 53 |
| Start date | Sep 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Oct 25, 2006 |
| Last update posted | Jan 4, 2017 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: